Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMWYP86)

• Drug Name: PD-0183812 Drug Info
• Synonyms: PETCVZZPKYJZAU-UHFFFAOYSA-N; PD183812; AC1NS8PJ; CHEMBL139653; SCHEMBL5268115; BDBM6280; PD 0183812; N8 Pyrido[2,3-d]pyrimidin-7-one deriv 72; 8-{bicyclo[221]heptan-2-yl}-2-({4-[4-(3-hydroxypropyl)piperidin-1-yl]phenyl}amino)-7H,8H-pyrido[2,3-d]pyrimidin-7-one; 8-(3-bicyclo[221]heptanyl)-2-[4-[4-(3-hydroxypropyl)piperidin-1-yl]anilino]pyrido[2,3-d]pyrimidin-7-one; PD0183813

Indication

Disease Entry	ICD 11	Status	REF
Retinoblastoma	2D02.2	Terminated	[1]

• Cross-matching ID:
  PubChem CID: 5330258
  TTD Drug ID: DMWYP86

Molecule-Related Drug Atlas

Drug(s) Targeting G1/S-specific cyclin-E1 (CCNE1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol	DMSKJ1X	Discovery agent	N.A.	Investigative	[4]
3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione	DMDO175	Discovery agent	N.A.	Investigative	[5]
3,4-diphenyl-1H-pyrrole-2,5-dione	DMPK6YT	Discovery agent	N.A.	Investigative	[5]
3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione	DMGC7RY	Discovery agent	N.A.	Investigative	[5]
BMS-536924	DMXJB4N	Discovery agent	N.A.	Investigative	[6]
3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione	DM3EV9N	Discovery agent	N.A.	Investigative	[5]
aloisine A	DM5U1LN	Discovery agent	N.A.	Investigative	[7]
3-((3,5-diamino-1H-pyrazol-4-yl)diazenyl)phenol	DMJZK40	Discovery agent	N.A.	Investigative	[4]
(2'Z,3'E)-5-Chloro-5'-chloro-indirubin-3'-oxime	DMGXRSZ	Discovery agent	N.A.	Investigative	[8]
(2'Z,3'E)-5-Chloro-5'-methyl-indirubin-3'-oxime	DMZ0V6G	Discovery agent	N.A.	Investigative	[8]

Drug(s) Targeting FGFR4 messenger RNA (FGFR4 mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ISIS-FGFR4	DMNVZDT	Obesity	5B81	Phase 2	[9]
FGF401	DMWEJ0C	Hepatocellular carcinoma	2C12.02	Phase 1/2	[10]
H3B-6527	DMAYTRK	Hepatocellular carcinoma	2C12.02	Phase 1	[10]
BLU-554	DM27J3D	Hepatocellular carcinoma	2C12.02	Phase 1	[10]
Ro-4396686	DM5DMCH	Discovery agent	N.A.	Investigative	[11]

Drug(s) Targeting Fibroblast growth factor receptor 1 (FGFR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Romiplostim	DM3U7SZ	Thrombocytopenia	3B64	Approved	[12]
Intedanib	DMSTA36	Colorectal cancer	2B91.Z	Approved	[13]
Pemigatinib	DM819JF	Cholangiocarcinoma	2C12.10	Approved	[14]
Infigratinib	DMNKBEC	Cholangiocarcinoma	2C12.10	Approved	[15]
E-3810	DM42PFT	Solid tumour/cancer	2A00-2F9Z	Phase 3	[16]
Sulfatinib	DMPOTM4	Neuroendocrine cancer	2B72.1	Phase 3	[17]
ARQ-087	DM02BVQ	Intrahepatic cholangiocarcinoma	2C12.10	Phase 3	[18]
AZD4547	DM3827C	Solid tumour/cancer	2A00-2F9Z	Phase 2/3	[19]
Debio 1347	DMZW50O	Solid tumour/cancer	2A00-2F9Z	Phase 2	[10]
AM-001	DMGVQI8	Actinic keratosis	EK90.0	Phase 2	[20]

Drug(s) Targeting Fibroblast growth factor receptor 2 (FGFR2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Pemigatinib	DM819JF	Cholangiocarcinoma	2C12.10	Approved	[14]
Interferon Alfa-2a, Recombinant	DMUTZ8S	Chronic HCV-1 infection	1E51.1	Approved	[21]
Palifermin	DM9JOYP	Oral mucositis	DA01.11	Approved	[22]
E-3810	DM42PFT	Solid tumour/cancer	2A00-2F9Z	Phase 3	[16]
Trafermin	DMLKI2B	Periodontitis	DA0C	Phase 3	[23]
Debio 1347	DMZW50O	Solid tumour/cancer	2A00-2F9Z	Phase 2	[10]
LY2874455	DMZ0DMY	Solid tumour/cancer	2A00-2F9Z	Phase 2	[24]
MK-2461	DM21WBH	Alzheimer disease	8A20	Phase 1/2	[25]
AEE-788	DMEOS5K	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[26]
BAY1179470	DM7L91K	Solid tumour/cancer	2A00-2F9Z	Phase 1	[27]

Drug(s) Targeting Cyclin A2 (CCNA2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol	DMSKJ1X	Discovery agent	N.A.	Investigative	[4]
aloisine A	DM5U1LN	Discovery agent	N.A.	Investigative	[7]
3-((3,5-diamino-1H-pyrazol-4-yl)diazenyl)phenol	DMJZK40	Discovery agent	N.A.	Investigative	[4]
MERIOLIN 8	DM0E95B	Discovery agent	N.A.	Investigative	[28]
2,5-dichloro-N-p-tolylthiophene-3-sulfonamide	DMU5J8Y	Discovery agent	N.A.	Investigative	[29]
Purvalanol A	DMNQ7TM	Discovery agent	N.A.	Investigative	[30]
MERIOLIN 1	DMJT93H	Discovery agent	N.A.	Investigative	[28]
MERIOLIN 4	DMIJMZQ	Discovery agent	N.A.	Investigative	[28]
MERIOLIN 6	DMW5AXC	Discovery agent	N.A.	Investigative	[28]
MERIOLIN 5	DMGVLR0	Discovery agent	N.A.	Investigative	[28]

Drug(s) Targeting Cyclin-dependent kinase 2 (CDK2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
R-roscovitine	DMSH108	Non-small-cell lung cancer	2C25.Y	Phase 2	[31]
Ro 31-7453	DM83QCL	Solid tumour/cancer	2A00-2F9Z	Phase 2	[26]
PHA848125	DMS2Q9G	Thymic cancer	2C27	Phase 2	[32]
TG02	DMZFIGQ	Anaplastic astrocytoma	2A00.0	Phase 1/2	[33]
NUV-422	DMQJQNT	Malignant glioma	2A00.0	Phase 1/2	[34]
RGB-286638	DMEGOQP	Haematological malignancy	2B33.Y	Phase 1	[35]
FN-1501	DM7BMD6	Solid tumour/cancer	2A00-2F9Z	Phase 1	[36]
AG-024322	DMY4WVK	Solid tumour/cancer	2A00-2F9Z	Phase 1	[31]
PHA-793887	DM2Y4FG	Solid tumour/cancer	2A00-2F9Z	Phase 1	[37]
SNS-032	DMEITAS	Solid tumour/cancer	2A00-2F9Z	Phase 1	[38]

Drug(s) Targeting Cyclin-dependent kinase 4 (CDK4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Apremilast	DMTWS9E	Psoriasis vulgaris	EA90	Approved	[39]
LY2835219	DM93VBZ	Breast cancer	2C60-2C65	Approved	[40]
Palbociclib	DMD7L94	Breast cancer	2C60-2C65	Approved	[41]
Ribociclib Succinate	DM9CIUW	Breast cancer	2C60-2C65	Approved	[42]
Trilaciclib	DMP5A4T	Small-cell lung cancer	2C25.Y	Approved	[43]
LEE011	DMMX75K	Breast cancer	2C60-2C65	Phase 3	[44]
Ro 31-7453	DM83QCL	Solid tumour/cancer	2A00-2F9Z	Phase 2	[26]
P276-00	DM9DJL2	Mantle cell lymphoma	2A85.5	Phase 2	[31]
P-276	DMMJUHD	Breast cancer	2C60-2C65	Phase 2	[45]
G1T38	DMQO2IT	Breast cancer	2C60-2C65	Phase 2	[10]

Drug(s) Targeting Cyclin-dependent kinase 6 (CDK6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Apremilast	DMTWS9E	Psoriasis vulgaris	EA90	Approved	[39]
LY2835219	DM93VBZ	Breast cancer	2C60-2C65	Approved	[40]
Palbociclib	DMD7L94	Breast cancer	2C60-2C65	Approved	[41]
Ribociclib Succinate	DM9CIUW	Breast cancer	2C60-2C65	Approved	[42]
Trilaciclib	DMP5A4T	Small-cell lung cancer	2C25.Y	Approved	[43]
LEE011	DMMX75K	Breast cancer	2C60-2C65	Phase 3	[44]
G1T38	DMQO2IT	Breast cancer	2C60-2C65	Phase 2	[10]
GLR2007	DM7DWLY	Glioblastoma of brain	2A00.00	Phase 1/2	[46]
FCN-437	DMQ8VUW	Breast cancer	2C60-2C65	Phase 1/2	[47]
NUV-422	DMQJQNT	Malignant glioma	2A00.0	Phase 1/2	[34]

Drug(s) Targeting Fibroblast growth factor receptor 3 (FGFR3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Pemigatinib	DM819JF	Cholangiocarcinoma	2C12.10	Approved	[14]
Trapidil	DMY67U8	Acute coronary syndrome	BA41	Phase 4	[48]
E-3810	DM42PFT	Solid tumour/cancer	2A00-2F9Z	Phase 3	[16]
TKI258	DMYLT67	Renal cell carcinoma	2C90	Phase 3	[26]
BMS-582664	DMDAN8H	Hepatocellular carcinoma	2C12.02	Phase 3	[26]
Debio 1347	DMZW50O	Solid tumour/cancer	2A00-2F9Z	Phase 2	[10]
B-701	DMOMDA4	Bladder cancer	2C94	Phase 2	[49]
Recifercept	DML8N3Y	Achondroplasia	LD24.00	Phase 2	[50]
MK-2461	DM21WBH	Alzheimer disease	8A20	Phase 1/2	[25]
AEE-788	DMEOS5K	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[26]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Cyclin A2 (CCNA2)	TTAMQ62	CCNA2_HUMAN	Inhibitor	[2]
Cyclin-dependent kinase 2 (CDK2)	TT7HF4W	CDK2_HUMAN	Inhibitor	[2]
Cyclin-dependent kinase 4 (CDK4)	TT0PG8F	CDK4_HUMAN	Inhibitor	[3]
Cyclin-dependent kinase 6 (CDK6)	TTO0FDJ	CDK6_HUMAN	Inhibitor	[3]
FGFR4 messenger RNA (FGFR4 mRNA)	TT1KX2S	FGFR4_HUMAN	Inhibitor	[2]
Fibroblast growth factor receptor 1 (FGFR1)	TTRLW2X	FGFR1_HUMAN	Inhibitor	[2]
Fibroblast growth factor receptor 2 (FGFR2)	TTGJVQM	FGFR2_HUMAN	Inhibitor	[2]
Fibroblast growth factor receptor 3 (FGFR3)	TTST7KB	FGFR3_HUMAN	Inhibitor	[2]
G1/S-specific cyclin-E1 (CCNE1)	TTCEJ4F	CCNE1_HUMAN	Inhibitor	[2]

References

• [1] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014130)
• [2] Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases. J Med Chem. 2000 Nov 30;43(24):4606-16.
• [3] Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci. 2002 Sep;23(9):417-25.
• [4] 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9.
• [5] Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
• [6] Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitum... J Med Chem. 2005 Sep 8;48(18):5639-43.
• [7] Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects. J Med Chem. 2003 Jan 16;46(2):222-36.
• [8] 5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity. J Med Chem. 2010 May 13;53(9):3696-706.
• [9] Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011).
• [10] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [11] Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1950-3.
• [12] Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. J Med Chem. 2002 Dec 19;45(26):5687-93.
• [13] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [14] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [15] Pharmacological inhibition of fibroblast growth factor (FGF) receptor signaling ameliorates FGF23-mediated hypophosphatemic rickets. J Bone Miner Res. 2013 Apr;28(4):899-911.
• [16] E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb 15;71(4):1396-405.
• [17] Clinical pipeline report, company report or official report of Hutchison Medi Pharma.
• [18] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1808).
• [19] AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res. 2012 Apr 15;72(8):2045-56.
• [20] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029917)
• [21] DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
• [22] Keratinocyte growth factor. Expert Opin Biol Ther. 2009 Jun;9(6):779-87.
• [23] Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24.
• [24] Company report (Eli Lilly) (drug: LY2874455)
• [25] MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33.
• [26] A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
• [27] National Cancer Institute Drug Dictionary (drug id 751593).
• [28] Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin com... J Med Chem. 2008 Feb 28;51(4):737-51.
• [29] Activity of substituted thiophene sulfonamides against malarial and mammalian cyclin dependent protein kinases, Bioorg. Med. Chem. Lett. 20(13):3863-3867 (2010).
• [30] The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.
• [31] Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
• [32] Identification of N,1,4,4-tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a potent, orally available cyclin dependent kinase inhibitor. J Med Chem. 2009 Aug 27;52(16):5152-63.
• [33] Preclinical metabolism and pharmacokinetics of SB1317 (TG02), a potent CDK/JAK2/FLT3 inhibitor. Drug Metab Lett. 2012 Mar;6(1):33-42.
• [34] ClinicalTrials.gov (NCT04541225) Phase 1/2 Dose Escalation, Safety, Pharmacokinetics, and Efficacy Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors. U.S.National Institutes of Health.
• [35] Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs. Leukemia. 2013 Dec;27(12):2366-75.
• [36] Discovery of 4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-Kinase Inhibitor with Potentially High Efficiency against Acute Myelocytic Leukemia. J Med Chem. 2018 Feb 22;61(4):1499-1518.
• [37] A first in man, phase I dose-escalation study of PHA-793887, an inhibitor of multiple cyclin-dependent kinases (CDK2, 1 and 4) reveals unexpected h... Cell Cycle. 2011 Mar 15;10(6):963-70.
• [38] Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2009 May 7;113(19):4637-45.
• [39] Agreement signed with Prostagenics to develop prostate cancer treatment. Innovate Oncology, Inc. 2005.
• [40] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [41] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2017
• [42] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [43] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
• [44] Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clin Cancer Res. 2013 Nov 15;19(22):6173-82.
• [45] Liposarcoma: molecular genetics and therapeutics. Sarcoma. 2011;2011:483154.
• [46] Clinical pipeline report, company report or official report of Gan & Lee Pharmaceuticals.
• [47] Clinical pipeline report, company report or official report of Fochon Pharmaceuticals.
• [48] Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
• [49] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [50] In vitro and in vivo characterization of Recifercept, a soluble fibroblast growth factor receptor 3, as treatment for achondroplasia. PLoS One. 2020 Dec 28;15(12):e0244368.